MD Anderson and RaySearch announce strategic alliance to advance radiation therapy of cancer
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with
the aim of enhancing cancer radiation therapy through several initiatives, including more precisely targeting of tumors
and improving upon, and making more available, an existing radiation therapy called adaptive radiation therapy (ART),
currently only used at highly specialized care centers.
Successful radiation therapy depends on the ability to delineate the precise tumor location. Since most radiation
treatments are delivered over several weeks, a number of variables can compromise treatment accuracy. Traditionally,
additional margins are set around the target area to allow for tumor movement and variations in how patients are
positioned during treatment.
However, these margins do not always compensate for unexpected changes in the tumor and surrounding normal tissue over
the full course of radiation treatment. Adaptive radiation therapy (ART) uses frequent imaging to give an up-to-date
assessment of physical changes and enable precisely tailored treatment for each patient.
The partnership, which builds upon a previously established relationship between RaySearch and MD Anderson centered on
RayCare®, RaySearch’s new oncology information system, combines MD Anderson’s clinical data and expertise with the
latest technology and platforms available through RaySearch and will focus on the following areas:
• Integration of advanced imaging into the treatment planning process to help define the tumor targets better.
• Management of changes in the tumor that may occur during treatment, and monitoring and adjusting treatment to
accommodate each patient’s individual circumstances at any point during therapy.
• Building software components with the aim of creating a new standard of care in radiation therapy.
“The technology to perform adaptive radiation therapy has been around for a number of years and studies have
demonstrated its advantages,” said Caroline Chung, M.D., assistant professor of Radiation Oncology at MD Anderson.
“However, it is a complex process that has not yet been broadly adopted in clinical practice and is largely limited to
highly specialized care centers. The goal of this collaboration is to establish a methodology and workflow, clinically
tested at MD Anderson, which can be streamlined and automated to enable adaptive radiation therapy on a larger scale.”
The combination of advanced imaging data, including platforms such as RayCare and the treatment planning system
RayStation, will be vital to improving the delineation of tumors. Together, this provides a novel opportunity for more
personalized treatment and the development of digital workflows has the potential to improve patient care at MD Anderson
and other cancer care facilities around the world.
“This strategic partnership between MD Anderson and RaySearch is an incredibly important milestone for RaySearch,” said
Johan Löf, Ph.D., CEO and founder of RaySearch. “It is one of the most ambitious collaborations that we have ever
engaged in. With RayStation and RayCare as the technological platforms, paired with the expertise of MD Anderson, I
believe that we can make tremendous progress toward our vision of a world where cancer is conquered.”
About MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to
cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center.
MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s
original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 45 National
Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s “Best Hospitals” survey has ranked MD Anderson the nation’s top hospital for cancer care. MD Anderson
has been ranked the leading cancer hospital for 11 of the past 14 years. The institution has been named one of the
nation's top two hospitals for cancer care every year since the survey began in 1990.
About RayStation
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system.
It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation
therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and
highly accurate dose engines for photon, electron and proton and carbon ion therapy. The system is built on the latest
software architecture and has a graphical user interface offering state-of-the-art usability.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for
improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and
distributes products through licensing agreements with leading medical technology companies. The company recently
launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch.
RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a
spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
To learn more about RaySearch, go to: www.raysearchlabs.com
* Subject to regulatory clearance in some markets.